Antengene Clears CDE Hurdle for Phase III Gastric Cancer Trial — Antengene Corporation Limited

Event summary

Antengene received CDE endorsement to initiate Phase III CLINCH-3 study for ATG-022 in CLDN18.2+ advanced gastric/GEJ cancer.
Study will compare ATG-022 against investigator's choice, with primary endpoints of PFS and OS.
Phase I/II CLINCH study showed ORRs of 46.7% and 40.0% at 1.8 mg/kg and 2.4 mg/kg, respectively.
ATG-022 demonstrated a favorable safety profile with 19.4% Grade 3+ TRAEs in the 1.8 mg/kg cohort.
Study led by Prof. Lin Shen from Peking University Cancer Hospital.

The big picture

Antengene's CDE endorsement for the Phase III CLINCH-3 study marks a critical step in validating its CLDN18.2-targeting ADC, ATG-022, as a potential best-in-disease therapy for advanced gastric cancer. The study's initiation underscores the company's ability to navigate regulatory pathways efficiently, particularly in China's increasingly influential biopharma market. With encouraging Phase I/II data and a favorable safety profile, ATG-022 could reshape treatment options for a disease with significant unmet medical needs, particularly in the third-line setting where current therapies offer limited benefits.

What we're watching

Clinical Execution: Whether Antengene can efficiently initiate and complete the Phase III CLINCH-3 study as a multi-regional clinical trial.
Regulatory Pathway: The pace at which CDE and other global regulators may approve ATG-022 for marketing.
Competitive Positioning: How ATG-022's differentiated efficacy and safety profile will position it against existing and emerging therapies for gastric cancer.